{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T05:54:10Z","timestamp":1775627650719,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,30]]},"DOI":"10.7759\/cureus.47954","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T10:05:33Z","timestamp":1698660333000},"source":"Crossref","is-referenced-by-count":2,"title":["Comparison of Outcomes Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients With Myocardial Infarction: A Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Johao","family":"Escobar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anurag","family":"Rawat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabricio","family":"Maradiaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham  K","family":"Isaak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sana","family":"Zainab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammedsefa","family":"Arusi Dari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Mekonen Gdey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Areeba","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial","volume":"360","author":"Dickstein K","year":"2002","unstructured":"Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet. 2002, 360:752-60. 10.1016\/s0140-6736(02)09895-1","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.24776","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions","volume":"82","author":"O'Gara PT","year":"2013","unstructured":"O'Gara PT, Kushner FG, Ascheim DD, et al.. 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv. 2013, 82:E1-27. 10.1002\/ccd.24776","journal-title":"Catheter Cardiovasc Interv"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Ibanez B","year":"2018","unstructured":"Ibanez B, James S, Agewall S, et al.. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018, 39:119-77. 10.1093\/eurheartj\/ehx393","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92693-N","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure","volume":"342","author":"The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","year":"1993","unstructured":"The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993, 342:821-8. 10.1016\/0140-6736(93)92693-N","journal-title":"Lancet"},{"key":"ref5","article-title":"Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease","author":"Baker WL","year":"2009","unstructured":"Baker WL, Coleman CI, Kluger J, et al.. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews. Centre for Reviews and Dissemination (UK), York, UK; 2009. 861-71."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.13.1905","article-title":"Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?","volume":"160","author":"Grossman E","year":"2000","unstructured":"Grossman E, Messerli FH, Neutel JM. Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?. Arch Intern Med. 2000, 160:1905-11. 10.1001\/archinte.160.13.1905","journal-title":"Arch Intern Med"},{"key":"ref7","article-title":"ACE inhibitors, angiotensin II antagonists and cough. The Losartan Cough Study Group","volume":"9 Suppl 5","author":"Ramsay LE","year":"1995","unstructured":"Ramsay LE, Yeo WW. ACE inhibitors, angiotensin II antagonists and cough. The Losartan Cough Study Group. J Hum Hypertens. 1995, 9 Suppl 5:S51-4.","journal-title":"J Hum Hypertens"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2021.05.002","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet JP","year":"2021","unstructured":"Collet JP, Thiele H, Barbato E, et al.. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021, 42:1289-136. 10.1016\/j.rec.2021.05.002","journal-title":"Eur Heart J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/s0735-1097(01)01714-4","article-title":"Neurohumoral and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure","volume":"39","author":"Tang WH","year":"2002","unstructured":"Tang WH, Vagelos RH, Yee YG, et al.. Neurohumoral and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol. 2002, 39:70-8. 10.1016\/s0735-1097(01)01714-4","journal-title":"J Am Coll Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/01.res.80.2.219","article-title":"Functional and biochemical analysis of angiotensin II-forming pathways in the human heart","volume":"80","author":"Wolny A","year":"1997","unstructured":"Wolny A, Clozel JP, Rein J, et al.. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res. 1997, 80:219-27. 10.1161\/01.res.80.2.219","journal-title":"Circ Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.33.2.613","article-title":"Recent progress in angiotensin II type 2 receptor research in the cardiovascular system","volume":"33","author":"Horiuchi M","year":"1999","unstructured":"Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension. 1999, 33:613-21. 10.1161\/01.hyp.33.2.613","journal-title":"Hypertension"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.1253\/circj.CJ-08-0115","article-title":"Angiotensin-receptor blockade reduces border zone myocardial monocyte chemoattractant protein-1 expression and macrophage infiltration in post-infarction ventricular remodeling","volume":"72","author":"Kohno T","year":"2008","unstructured":"Kohno T, Anzai T, Naito K, et al.. Angiotensin-receptor blockade reduces border zone myocardial monocyte chemoattractant protein-1 expression and macrophage infiltration in post-infarction ventricular remodeling. Circ J. 2008, 72:1685-92.","journal-title":"Circ J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2018.08.038","article-title":"Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and non-ST-segment elevation myocardial infarction who underwent successful percutaneous coronary intervention","volume":"277","author":"Byun JK","year":"2018","unstructured":"Byun JK, Choi BG, Rha SW, Choi SY, Jeong MH. Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and non-ST-segment elevation myocardial infarction who underwent successful percutaneous coronary intervention. Atherosclerosis. 2018, 277:130-5. 10.1016\/j.atherosclerosis.2018.08.038","journal-title":"Atherosclerosis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0290251","article-title":"Comparison of clinical outcomes of angiotensin receptor blockers with angiotensin-converting enzyme inhibitors in patients with acute myocardial infarction","volume":"18","author":"Chen CW","year":"2023","unstructured":"Chen CW, Chang CW, Lin YC, Chen WT, Chien LN, Huang CY. Comparison of clinical outcomes of angiotensin receptor blockers with angiotensin-converting enzyme inhibitors in patients with acute myocardial infarction. PLoS One. 2023, 18:e0290251. 10.1371\/journal.pone.0290251","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/1074248418795897","article-title":"Angiotensin-converting enzyme inhibitors provide better long-term survival benefits to patients with AMI than angiotensin II receptor blockers after survival hospital discharge","volume":"24","author":"Choi IS","year":"2019","unstructured":"Choi IS, Park IB, Lee K, et al.. Angiotensin-converting enzyme inhibitors provide better long-term survival benefits to patients with AMI than angiotensin II receptor blockers after survival hospital discharge. J Cardiovasc Pharmacol Ther. 2019, 24:120-9. 10.1177\/1074248418795897","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2014.03.055","article-title":"Comparison of 5-year survival after acute myocardial infarction using angiotensin-converting enzyme inhibitor versus angiotensin II receptor blocker","volume":"114","author":"Hara M","year":"2014","unstructured":"Hara M, Sakata Y, Nakatani D, et al.. Comparison of 5-year survival after acute myocardial infarction using angiotensin-converting enzyme inhibitor versus angiotensin II receptor blocker. Am J Cardiol. 2014, 114:1-8. 10.1016\/j.amjcard.2014.03.055","journal-title":"Am J Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0242314","article-title":"The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension","volume":"15","author":"Her AY","year":"2020","unstructured":"Her AY, Choi BG, Rha SW, Kim YH, Choi CU, Jeong MH. The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension. PLoS One. 2020, 15:e0242314. 10.1371\/journal.pone.0242314","journal-title":"PLoS One"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.54912\/jci.2023.0008","article-title":"Losartan versus ramipril on 3-year clinical outcomes after acute myocardial infarction in Korean population: from the Korea acute myocardial infarction registry-National Institutes of Health","volume":"2","author":"Hyun SJ","year":"2023","unstructured":"Hyun SJ, Byun JK, Rha SW, et al.. Losartan versus ramipril on 3-year clinical outcomes after acute myocardial infarction in Korean population: from the Korea acute myocardial infarction registry-National Institutes of Health. JACC Cardiovasc Interv. 2023, 2:249-59. 10.54912\/jci.2023.0008","journal-title":"JACC Cardiovasc Interv"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-021-02070-x","article-title":"Impact of renin angiotensin system inhibitor on 3-year clinical outcomes in acute myocardial infarction patients with preserved left ventricular systolic function: a prospective cohort study from Korea Acute Myocardial Infarction Registry (KAMIR)","volume":"21","author":"Kim KH","year":"2021","unstructured":"Kim KH, Choi BG, Rha SW, et al.. Impact of renin angiotensin system inhibitor on 3-year clinical outcomes in acute myocardial infarction patients with preserved left ventricular systolic function: a prospective cohort study from Korea Acute Myocardial Infarction Registry (KAMIR). BMC Cardiovasc Disord. 2021, 21:251. 10.1186\/s12872-021-02070-x","journal-title":"BMC Cardiovasc Disord"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2019-001010","article-title":"Comparative effectiveness of ACE inhibitors and angiotensin receptor blockers in patients with prior myocardial infarction","volume":"6","author":"Ko D","year":"2019","unstructured":"Ko D, Azizi P, Koh M, Chong A, Austin P, Stukel T, Jackevicius C. Comparative effectiveness of ACE inhibitors and angiotensin receptor blockers in patients with prior myocardial infarction. Open Heart. 2019, 6:e001010. 10.1136\/openhrt-2019-001010","journal-title":"Open Heart"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2014.268","article-title":"Angiotensin II type 1 receptor blockers as a first choice in patients with acute myocardial infarction","volume":"31","author":"Lee JH","year":"2016","unstructured":"Lee JH, Bae MH, Yang DH, et al.. Angiotensin II type 1 receptor blockers as a first choice in patients with acute myocardial infarction. Korean J Intern Med. 2016, 31:267-76. 10.3904\/kjim.2014.268","journal-title":"Korean J Intern Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0281460","article-title":"Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction","volume":"18","author":"Lee JG","year":"2023","unstructured":"Lee JG, Joo SJ, Kim SY, et al.. Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction. PLoS One. 2023, 18:e0281460. 10.1371\/journal.pone.0281460","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2019.34.e289","article-title":"Angiotensin receptor blockers as an alternative to angiotensin-converting enzyme inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention","volume":"34","author":"Lim S","year":"2019","unstructured":"Lim S, Choo EH, Choi IJ, et al.. Angiotensin receptor blockers as an alternative to angiotensin-converting enzyme inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention. J Korean Med Sci. 2019, 34:e289. 10.3346\/jkms.2019.34.e289","journal-title":"J Korean Med Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer MA","year":"2003","unstructured":"Pfeffer MA, McMurray JJ, Velazquez EJ, et al.. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003, 349:1893-906. 10.1056\/NEJMoa032292","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13644","article-title":"ARNI versus ACEI\/ARB in reducing cardiovascular outcomes after myocardial infarction","volume":"8","author":"She J","year":"2021","unstructured":"She J, Lou B, Liu H, et al.. ARNI versus ACEI\/ARB in reducing cardiovascular outcomes after myocardial infarction. ESC Heart Fail. 2021, 8:4607-16. 10.1002\/ehf2.13644","journal-title":"ESC Heart Fail"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-015-0140-5","article-title":"Comparative effectiveness of angiotensin II receptor blockers versus angiotensin-converting enzyme inhibitors following contemporary treatments in patients with acute myocardial infarction: results from the Korean working group in myocardial infarcti","volume":"15","author":"Song PS","year":"2015","unstructured":"Song PS, Seol SH, Seo GW, et al.. Comparative effectiveness of angiotensin II receptor blockers versus angiotensin-converting enzyme inhibitors following contemporary treatments in patients with acute myocardial infarction: results from the Korean working group in myocardial infarcti. Am J Cardiovasc Drugs. 2015, 15:439-49. 10.1007\/s40256-015-0140-5","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1253\/circj.cj-08-0959","article-title":"Inhibitory effect of valsartan against progression of left ventricular dysfunction after myocardial infarction: T-VENTURE study","volume":"73","author":"Suzuki H","year":"2009","unstructured":"Suzuki H, Geshi E, Nanjyo S, et al.. Inhibitory effect of valsartan against progression of left ventricular dysfunction after myocardial infarction: T-VENTURE study. Circ J. 2009, 73:918-24. 10.1253\/circj.cj-08-0959","journal-title":"Circ J"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf S","year":"2008","unstructured":"Yusuf S, Teo KK, Pogue J, et al.. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008, 358:1547-59. 10.1056\/NEJMoa0801317","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.10.011","article-title":"A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure","volume":"61","author":"Savarese G","year":"2013","unstructured":"Savarese G, Costanzo P, Cleland JG, Vassallo E, Ruggiero D, Rosano G, Perrone-Filardi P. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol. 2013, 61:131-42. 10.1016\/j.jacc.2012.10.011","journal-title":"J Am Coll Cardiol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM19951221333250","article-title":"A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril cardiac evaluation (TRACE) study group","volume":"333","author":"Kober L","year":"1995","unstructured":"Kober L, Torp-Pedersen C, Carlsen JE, et al.. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril cardiac evaluation (TRACE) study group. N Engl J Med. 1995, 333:1670-6. 10.1056\/NEJM19951221333250","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90232-1","article-title":"GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction","volume":"343","author":"Gruppo Italiano per lo Studio della Soprawivenza nell'Infarto Miocardico","year":"1994","unstructured":"Gruppo Italiano per lo Studio della Soprawivenza nell'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994, 343:1115-22. 10.1016\/S0140-6736(94)90232-1","journal-title":"Lancet"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe0801925","article-title":"ACE inhibitors in cardiovascular disease\u2014unbeatable?","volume":"358","author":"McMurray JJ","year":"2008","unstructured":"McMurray JJ. ACE inhibitors in cardiovascular disease\u2014unbeatable?. N Engl J Med. 2008, 358:1615-6. 10.1056\/NEJMe0801925","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g6650","article-title":"Angiotensin receptor blocker in patients with ST segment elevation myocardial infarction with preserved left ventricular systolic function: prospective cohort study","volume":"349","author":"Yang JH","year":"2014","unstructured":"Yang JH, Hahn JY, Song YB, et al.. Angiotensin receptor blocker in patients with ST segment elevation myocardial infarction with preserved left ventricular systolic function: prospective cohort study. BMJ. 2014, 349:g6650. 10.1136\/bmj.g6650","journal-title":"BMJ"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/201797-comparison-of-outcomes-between-angiotensin-converting-enzyme-inhibitors-and-angiotensin-ii-receptor-blockers-in-patients-with-myocardial-infarction-a-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:08:55Z","timestamp":1707509335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/201797-comparison-of-outcomes-between-angiotensin-converting-enzyme-inhibitors-and-angiotensin-ii-receptor-blockers-in-patients-with-myocardial-infarction-a-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.47954","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,30]]}}}